In a report published online Oct. 19 in the British Journal of Dermatology, Ribero’s group analyzed data from almost 3,700 white twins in the United Kingdom who underwent a mole count on 17 body areas. The results showed that the mole depend on the right arm was the most predictive of the full total number of moles on a person’s entire body. For example, women with more than seven moles on their right arm had a ninefold increased threat of having more than 50 moles on their body. Those with more than 11 moles on their right arm were much more likely to have more than 100 moles on their body, placing them at higher risk for melanoma, the researchers said.In 2001, the FDA cautioned a Vioxx advertising campaign which denied the heart attack risks surfacing in link with the medication. Neither Vioxx producer Merck & Co. Nor Pfizer Inc., making Bextra and Celebrex, will agree to forego direct-to-consumer ads completely if the FDA requests it voluntarily, and might take up a legal battle if the FDA seeks a court injunction. Pfizer honored the FDA’s request for a suspension of consumer advertisements for Celebrex after Merck’s voluntary withdrawal of Vioxx from the market this past year raised issues that the whole COX-2 group increased center risks. Both businesses are negotiating with the FDA over possible changes to the medication labels that could consist of safety warnings.